Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Luisa L. Villa, Kevin A. Ault, Anna R. Giuliano, Ronaldo L.R. Costa, Carlos A. Petta, Rosires P. Andrade, Darron R. Brown, Alex Ferenczy, Diane M. Harper, Laura A. Koutsky, Robert J. Kurman, Matti Lehtinen, Christian Malm, Sven Eric Olsson, Brigitte M. Ronnett, Finn Egil Skjeldestad, Margareta Steinwall, Mark H. Stoler, Cosette M. Wheeler, Frank J. TaddeoJimmy Yu, Lisa Lupinacci, Radha Railkar, Rocio Marchese, Mark T. Esser, Janine Bryan, Kathrin U. Jansen, Heather L. Sings, Gretchen M. Tamms, Alfred J. Saah, Eliav Barr

Research output: Contribution to journalArticle

303 Scopus citations

Abstract

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.

Original languageEnglish (US)
Pages (from-to)5571-5583
Number of pages13
JournalVaccine
Volume24
Issue number27-28
DOIs
StatePublished - Jul 7 2006

Keywords

  • Human papillomavirus
  • Immunogenicity
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18'. Together they form a unique fingerprint.

  • Cite this

    Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L. R., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A., Harper, D. M., Koutsky, L. A., Kurman, R. J., Lehtinen, M., Malm, C., Olsson, S. E., Ronnett, B. M., Skjeldestad, F. E., Steinwall, M., Stoler, M. H., Wheeler, C. M., ... Barr, E. (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24(27-28), 5571-5583. https://doi.org/10.1016/j.vaccine.2006.04.068